Please login to the form below

Pneumococcal vaccine

This page shows the latest Pneumococcal vaccine news and features for those working in and with pharma, biotech and healthcare.

Pfizer eyes 20-strain Prevnar filing this year, after phase 3 win

New-generation shot could protect franchise from rival Merck &Co. Pfizer says it could be on course to file for approval of its new generation pneumococcal conjugate vaccine in the US ... Pneumococcal disease is caused by Streptococcus pneumoniae, and

Latest news

Solid Q1 results lift Pfizer as it waits for pipeline boost

Pfizer’s Prevnar pneumococcal vaccine franchise grew 8% to $1.49bn, around $100m ahead of expectations, although analysts expressed concerns that Pfizer was at risk of falling behind in the race
Pfizer’s Prevnar-13 successor takes aim at Merck rival

Rivals look to broaden coverage across strains. Pfizer just got a leg-up in its race with Merck &Co to bring a new-generation pneumococcal vaccine to the US market after ... is in pursuit of PCV-15 (also known as V114), a 15-valent candidate that Merck
Takeda's once-weekly DPP-4 inhibitor cleared in first market

The company also won Japanese approval for acne therapy Duac Combination Gel (clindamycin and benzoyl peroxide) and pneumococcal conjugate paediatric vaccine Synflorix. -
Pfizer's Prevenar 13 price cut slammed by MSF

Pfizer has reduced the price of its pneumococcal vaccine Prevenar 13 for an immunisation programme targeting low-income countries, but has been criticised for not going far enough. ... However, medical charity Medecins Sans Frontieres (MSF) said the
CHMP thumbs up for Novo's obesity drug Saxenda

Prevenar 13 also backed. Meanwhile, the CHMP has also issued a positive opinion for an application by Pfizer to extend the indications for its pneumococcal vaccine Prevenar 13 to include the ... prevention of pneumonia caused by the 13 pneumococcal

More from news
Approximately 1 fully matching, plus 35 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma leaders to watch in 2020

pneumococcal vaccine due to be filed next year that would extend its $3.4bn Prevnar franchise, a Clostridium difficile vaccine in phase 3 and JAK inhibitors for atopic dermatitis and alopecia.
Deal Watch table for March 2014

26.6. ‡SK Chemicals/ Sanofi Pasteur. Collaboration. Pneumococcal conjugate vaccine (PCV). 23.
A tailored approach to the BRIC markets

In 2009, GSK signed a 1.5bn deal with the Brazilian government to provide Syflorix, its vaccine for paediatric pneumococcal disease, at around a third of the price it charged in ... Europe. The deal guaranteed GSK a set price and set volumes for the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Taking a holistic approach to patient care: The importance of recognising each patient as an individual...
The concordance conundrum – the tech divide: “Hello? Can you hear me? I think you are on mute” – how many times have we all heard this over the past five or so months? Not exactly the...
3 ways to increase patient retention rates in clinical trials: Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....